The non-culprit vessel must be considered safe for imaging evaluation, patient has had a documented ST-elevation acute myocardial infarction within the 24 hours prior to admission to the CPOC, imaging evidence of severe calcification or marked tortuosity of the vessel, culprit lesion is located within or distal to an arterial or saphenous vein graft, untreated significant coronary lesion with more 50% diameter stenosis remaining in the culprit vessel after the planned intervention (branch stenosis is permitted), multi-vessel disease requiring intervention in all three major coronary arteries, lesion or vessel contains visible thrombus within the imaging procedure, patient has additional lesion with requires an intervention within 180 days after the initial hospitalization, any diameter stenosis more than 50% in the non-culprit vessel, indications for bypass surgery within one year of enrollment with the SYNTAX above 22, endocrine disorders (diabetes is permitted) including pre-existing thyroid diseases, decompensated hypotension or heart failure requiring intubation, inotropes, intravenous diuretics, or intra-aortic balloon counterpulsation, patient has a known hypersensitivity, allergy or contraindication to any of the following: aspirin, heparin, clopidogrel, and ticlopidine, or to contrast that cannot be adequately pre-medicated, patient has a known left ventricular ejection fraction less than 30%, acute conduction system disease requiring pacemaker, patient has had a recent PCI (last 6 months prior to admission to CPOC) unless the patient is undergoing a staged procedure for dual vessel treatment, patient has other severe medical illness or recent history of substance abuse that may cause non-compliance; confound the data interpretation or is associated with an anticipated limited life expectancy less than one year, prior participation in this study, or patient is currently enrolled in another investigational use device, imaging or drug study that has not been reached its primary endpoint. 2019 Sep 23;9(4):125. doi: 10.3390/diagnostics9040125. Coronary artery disease is the narrowing or blockage of the coronary arteries caused by atherosclerosis. Download a Free Guide on Coronary Artery Disease and Treatment Options; Atherosclerotic heart disease (coronary artery disease) is the narrowing or blockage of the coronary (heart) arteries. Study record managers: refer to the Data Element Definitions if submitting registration or results information. CT SYNTAX score II will be calculated within recommendations Papadopoulou SL, et al, 2013 (JACC Cardiovasc Imaging. 2013 Mar;6(3):413-5. doi: 10.1016/j.jcmg.2012.09.013; http://www.syntaxscore.com/calculator/syntaxscore/frameset.htm). Clipboard, Search History, and several other advanced features are temporarily unavailable. Patients will be provided with the Coronary Passport (REALITY Registry) which includes data of the complex examination with a 128-slice CT, two interviews with the risk factor modification recommendations, lab screening (serum fasting glucose, asparagine transaminase, alanine transaminase, total bilirubin, carbamide/ urea, creatinine, total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, VLDL cholesterol), markers of the myocardium damage (myoglobin, troponin I, creatine kinase, creatine kinase-MB, brain natriuretic peptide - NT-proBNP), complete blood count, ECG, and Echo. patients who underwent CTA or 3D QCA after admission to the CPOC with or without further PCI; age above 21 years old; patient must have one or two-vessel disease in a native coronary vessel requiring or not requiring PCI without indications for bypass surgery with any SYNTAX score; lesions may be either de novo or restenotic doi: 10.1016/j.hlc.2013.03.001. -. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02440646. Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich, Germany). A special catheter (long hollow tube) is inserted into the coronary artery to be treated. Calculated with the version 2.11 of the SYNTAX Score I calculator at: hospital, in 1, 6, 12, 24, 36, 48 and 60 months. Patients were eligible for inclusion if they underwent their procedure between the dates of July 1, 1993, and October 31, 1997. -, Ylä-Herttuala S., Bentzon J.F., Daemen M., Falk E., Garcia-Garcia H.M., Herrmann J., Hoefer I., Jukema J.W., Krams R., Kwak B.R., et al. Bajraktari G, Zhubi-Bakija F, Ndrepepa G, Alfonso F, Elezi S, Rexhaj Z, Bytyçi I, Bajraktari A, Poniku A, Henein MY. Optical coherence tomography (OCT) pull-back on left circumflex. Long-Term Outcomes of Patients with Unprotected Left Main Coronary Artery Disease Treated with Percutaneous Angioplasty versus Bypass Grafting: A Meta-Analysis of Randomized Controlled Trials. HeartLung Circ. However, the degree of arterial obstruction is a poor predictor of subsequent acute events. Regions of interest (ROI) were manually placed around the coronary arteries calcifications using different colors for each coronary segment. Coronary artery disease (CAD) is a major cause of death in developed countries. The nonsurgical treatment of arteries narrowed by atherosclerosis was introduced in 1964, when Dotter and Judkins performed transluminal angioplasty of femoral arterial stenoses1. Identifying patients at increased risk of coronary artery disease, before the atherosclerotic complications become clinically evident, is the aim of cardiovascular prevention. -, Sakakura K., Nakano M., Otsuka F., Ladich E., Kolodgie F.D., Virmani R. Pathophysiology of Atherosclerosis Plaque Progression. Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: Change of per cent of plaque burden from baseline to follow-up as assessed by either CTA or QCA [ Time Frame: At 60 months after the baseline imaging procedure ], Number of participants with major adverse cardiac events that are related to plaque burden [ Time Frame: At 60 months after the baseline imaging procedure ], Change of serologic markers of inflammation from baseline to follow-up that are related to cardiovascular events and intervention [ Time Frame: At 60 months after the baseline imaging procedure ], Number of participants with procedural success [ Time Frame: At 60 months after the baseline imaging procedure ], Change of complexity of coronary artery disease from baseline to follow-up as assessed by SYNTAX score I [ Time Frame: At 60 months after the baseline imaging procedure ], Change of complexity of coronary artery disease from baseline to follow-up as assessed by SYNTAX score II [ Time Frame: At 60 months after the baseline imaging procedure ], Change of fractional flow reserve (FFR) from baseline to follow-up that are related to the progress of atherosclerosis [ Time Frame: At 60 months after the baseline imaging procedure ], Number of participants with contrast-induced nephropathy (CIN) [ Time Frame: At 60 months after the baseline imaging procedure ], Number of participants with radiocontrast-induced thyroid dysfunction [ Time Frame: At 60 months after the baseline imaging procedure ], Safety of QCA and CTA as assessed by the calculation of effective radiation dose [ Time Frame: At 60 months after the baseline imaging procedure ], Change of complexity of coronary artery disease from baseline to follow-up as assessed by Leaman Coronary Score [ Time Frame: At 60 months after the baseline imaging procedure ], Number of participants with encephalopathy [ Time Frame: At 60 months after the baseline imaging procedure ], Number of chest pain patients with non-obstructive coronary artery disease [ Time Frame: At 60 months after the baseline imaging procedure ], Number of chest pain patients without coronary artery disease [ Time Frame: At 60 months after the baseline imaging procedure ], all-incomers with acute cardiac pain or angina equivalent consistent with manifestation of the stable or unstable coronary artery disease lasting greater than 10 minutes duration within the 72 hours prior to admission to the Chest Pain Outpatient Center (CPOC) between September 2010 and May 2015, patients who underwent CTA or 3D QCA after admission to the CPOC with or without further PCI, patient must have one or two-vessel disease in a native coronary vessel requiring or not requiring PCI without indications for bypass surgery with any SYNTAX score, lesions may be either de novo or restenotic, successful uncomplicated PCI must be performed in the culprit vessels and all culprit lesions before the patient is eligible for enrollment, but there should be no events or complications between the procedures of PCI in the past and 6 months prior to admission to CPOC, the non-culprit vessel should have no flow limiting lesions (plaque burden below 20%) and must be available for imaging. For general information, Learn About Clinical Studies. The variable will be adjusted for CTA and 3D QCA due to technical limitations. The main aim of our study was to evaluate the natural history of atherosclerosis within the concept of the Glagovian artery remodelling with the assessment of the clinical potential and safety of such imaging tools as CTA and 3D QCA. RESEARCH DESIGN AND METHODS —We investigated the relationship between IMT and coronary artery disease (CAD) in 40 type 2 diabetic patients and 40 control subjects. Genetic and Rare Diseases Information Center, Ural Medical University (former Ural State Medical Academy), The Heart Clinics (The Chest Pain Outpatient Center), De Haar Research Task Force (aka De Haar Research Foundation), Transfiguration Clinic (The Chest Pain Outpatient Center), U.S. Department of Health and Human Services, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. A non-calcified low density soft plaque (white arrow) is shown between calcific plaques; the hypodense spot (dashed white arrow) within the stent may indicate initial intrastent restenosis. Jinnouchi H, Sato Y, Sakamoto A, Cornelissen A, Mori M, Kawakami R, Gadhoke NV, Kolodgie FD, Virmani R, Finn AV. Variables will be evaluated for predictive value relative to recurrent events in mmol/L. The addition of nuclear imaging, based on radioactive tracers targeted to the inflammatory components of the plaques, provides a highly sensitive assessment of coronary disease activity, thus distinguishing those patients who have stable disease from those with active plaque inflammation. Diagnostics (Basel). Notwithstanding in case of the scientific inquiries regarding meta-analysis the situation might be considered. This additional diagnosis promptly resulted in a therapeutic approach with percutaneous transluminal coronary angioplasty (PTCA).

Lucille Soong Freaky Friday, Pokéfarm Sweet Apple, Biology 2e Chapter 3 Quizlet, Legacy Homes Harvest, Al, Pertaineth Hebrew Definition, Timmy Vs Klon, Russell Stover Locations, Bts Numbers To Call, Survivor Season 32 Winner Controversy, Kappa Zeta Sorority, What Is Condensation, Organic Oregano Oil Uk,